Headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.357250353474 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
A number of equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday. Wedbush reiterated a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, December 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, March 28th. BMO Capital Markets lifted their price target on shares of Intercept Pharmaceuticals from $152.00 to $155.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, Oppenheimer reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Thursday, February 15th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. Intercept Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $128.90.
Intercept Pharmaceuticals stock opened at $71.98 on Thursday. Intercept Pharmaceuticals has a 1 year low of $51.05 and a 1 year high of $135.59. The company has a market capitalization of $2,180.80, a P/E ratio of -5.01 and a beta of -1.82. The company has a quick ratio of 4.31, a current ratio of 4.31 and a debt-to-equity ratio of 21.71.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The company had revenue of $37.69 million during the quarter, compared to analysts’ expectations of $39.01 million. During the same quarter in the previous year, the firm posted ($4.84) earnings per share. Intercept Pharmaceuticals’s revenue for the quarter was up 173.1% compared to the same quarter last year. research analysts predict that Intercept Pharmaceuticals will post -12.6 earnings per share for the current year.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski acquired 7,812 shares of the firm’s stock in a transaction on Monday, April 9th. The stock was bought at an average cost of $64.00 per share, for a total transaction of $499,968.00. Following the completion of the purchase, the chief executive officer now directly owns 11,642 shares in the company, valued at $745,088. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Keith Michael Gottesdiener acquired 1,171 shares of the firm’s stock in a transaction on Monday, April 9th. The shares were acquired at an average price of $64.00 per share, with a total value of $74,944.00. Following the completion of the purchase, the director now owns 5,001 shares of the company’s stock, valued at $320,064. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 399,608 shares of company stock valued at $25,574,912. 4.50% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/19/intercept-pharmaceuticals-icpt-getting-somewhat-favorable-press-coverage-analysis-finds.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.